hyperpolarized pyruvate +/-urea (13C/15N)

Phase 2Small molecule

hyperpolarized pyruvate +/-urea (13C/15N) is one of 57 small molecule programs targeting Glioma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

Prostate CancerActive, not recruiting

GliomaPhase 1

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Preclinical

5 2

Mekinist

Novartis

Preclinical

3 3

Trexall

Alnylam Pharmaceuticals

Preclinical

—4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 5

hyperpolarized pyruvate +/-urea (13C/15N)

RRobert Bok, MD, PhD

Phase 2

1 6

Viagra

VViatris Specialty LLC

Preclinical

1 7

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 8

Triptorelin Pamoate

Ipsen

Preclinical

2 9

Ifex

BBaxter Healthcare Corporation

Preclinical

—10

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Glioma

NCT05851378

Q4 2032

Phase 2Recruiting

Prostate Cancer

NCT06391034

Clinical

Trials by Indication[1]

Glioma1 trial

Hyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant Glioma

Recruiting·RRobert Bok, MD, PhD·Phase 1·NCT05851378·40 enrolled

Prostate Cancer1 trial

Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer

Recruiting·RRobert Bok, MD, PhD·Phase 2·NCT06391034·161 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for hyperpolarized pyruvate +/-urea (13C/15N). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — hyperpolarized pyruvate +/-urea (13C/15N) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for hyperpolarized pyruvate +/-urea (13C/15N). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Robert Bok, MD, PhD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: RRobert Bok, MD, PhD

hyperpolarized pyruvate +/-urea (13C/15N)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2032

Trials by Indication[1]

Glioma1 trial

Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News